Cubist Pharma Revenue, Profits - CBST Annual Income Statement

Add to My Stocks
$101.94 $0.14 (0.14%) CBST stock closing price Jan 21, 2015 (Closing)

Fundamental analysis of CBST stock involves analyzing its financial statements, apart from checking the Cubist Pharma stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. Like any other income statement, the CBST income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue growth of 13.83% when compared to the same period in the past. The Cubist Pharma profit and loss statement for 2013 shows a net profit of $-18.57M. Profits for last year was $154.07M. Apart from this an investor should also check Cubist Pharma assets and Cubist Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec201320122011201020092008
Cubist Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)260.31M230.05M172.86M140.76M116.88M90.38M
Cubist Pharma Gross Profit
Research & Development Expense477.74M277.72M184.53M157.85M170.57M126.67M
Selling General & Admin Expense289.98M181.46M264.04M148.24M136.92M125.7M
Income Before Depreciation Depletion Amortization26.41M237.1M132.53M189.59M137.76M90.88M
Depreciation Depletion Amortization------
Non Operating Income-32.45M-4.51M3.67M-9.71M3.03M-35.64M
Interest Expense37.6M32.99M31.41M25.58M20.89M9.34M
Cubist Pharma Pretax Income
Provision for Income Taxes-25.07M45.52M71.76M59.98M40.3M-123.91M
Investment Gains Losses------
Other Income------
Income Before Extraordinaries & Disc Operations-18.57M154.07M33.02M94.32M79.6M169.81M
Extraordinary Items & Discontinued Operations------
Cubist Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS68.16M83.41M81.91M62.66M68.38M67.96M
Average Shares used to compute Basic EPS68.16M63.77M60.84M58.8M57.75M56.65M
Income Before Nonrecurring Items116.16M212.31M95.18M105.69M84.23M111.03M
Income from Nonrecurring Items-134.73M-58.23M-62.16M-11.37M-4.63M58.79M
Cubist Pharma Earnings Per Share Basic Net
Cubist Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items1.472.651.371.731.431.70
Preferred Dividends Acc Pd------
Dividends Common------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Cubist Pharma stock analysis involves checking at least a few of the important things like:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that CBST stock has a topline or revenue of $1.05B for 2013 as per this Cubist Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. CBST stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The CBST financials along with Cubist Pharma historical stock prices provide a lot of details about the firm.

Annual Income Statements - Cubist Pharmaceuticals Inc Industry Peers

AMNEAL PHARMACT income statement, Jazz Pharma income statement, Receptos income statement